{"id":91321,"date":"2026-05-19T11:48:26","date_gmt":"2026-05-19T06:18:26","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=91321"},"modified":"2026-05-19T11:48:27","modified_gmt":"2026-05-19T06:18:27","slug":"goldline-pharmaceutical-ipo-listing-today-19-may-2026","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/goldline-pharmaceutical-ipo-listing-today-19-may-2026\/","title":{"rendered":"Goldline Pharmaceutical IPO Listing Today 19 May 2026: 2026 Most Subscribed SME IPO at 841x Debuts on BSE SME \u2014 Opened at Rs 59.87, Trades at Rs 56.77 (+32%)"},"content":{"rendered":"<p><strong>The Goldline Pharmaceutical IPO listing<\/strong> takes place today at 10 AM on BSE SME, 19 May 2026. The Rs 11.61 crore issue attracted bids worth over Rs 9,800 crore \u2014 840.74 times the issue size \u2014 making it the most oversubscribed SME IPO of 2026 so far, per News9Live. The NII category was subscribed an extraordinary 1,662.04 times, retail 881.15 times and QIBs 180.22 times. The stock opened at approximately Rs 59.87 on BSE SME at 9:40 AM, a 39.2 percent premium over the Rs 43 issue price. It then dropped sharply to Rs 56.66 by 11:50 AM as anticipated NII selling pressure hit. The stock has since stabilised and is currently trading at Rs 56.77, up Rs 13.77 or 32.02 percent from the issue price.<\/p><div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/goldline-pharmaceutical-ipo-listing-today-19-may-2026\/#Goldline_Pharmaceutical_IPO_Listing_Complete_Data\" title=\"Goldline Pharmaceutical IPO Listing: Complete Data\">Goldline Pharmaceutical IPO Listing: Complete Data<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/goldline-pharmaceutical-ipo-listing-today-19-may-2026\/#Actual_Listing_Opened_at_Rs_5987_Corrected_to_Rs_5677_32_%E2%80%94_How_It_Played_Out\" title=\"Actual Listing: Opened at Rs 59.87, Corrected to Rs 56.77 (+32%) \u2014 How It Played Out\">Actual Listing: Opened at Rs 59.87, Corrected to Rs 56.77 (+32%) \u2014 How It Played Out<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/goldline-pharmaceutical-ipo-listing-today-19-may-2026\/#840x_Subscription_Breakdown_What_Each_Category_Means\" title=\"840x Subscription Breakdown: What Each Category Means\">840x Subscription Breakdown: What Each Category Means<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/goldline-pharmaceutical-ipo-listing-today-19-may-2026\/#NII_at_1662x_%E2%80%94_Record_HNI_Demand_But_Small_Allotments\" title=\"NII at 1,662x \u2014 Record HNI Demand, But Small Allotments\">NII at 1,662x \u2014 Record HNI Demand, But Small Allotments<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/goldline-pharmaceutical-ipo-listing-today-19-may-2026\/#Retail_at_881x_%E2%80%94_Lottery_Winners_Have_Strong_Gains\" title=\"Retail at 881x \u2014 Lottery Winners Have Strong Gains\">Retail at 881x \u2014 Lottery Winners Have Strong Gains<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/goldline-pharmaceutical-ipo-listing-today-19-may-2026\/#QIB_at_180x_%E2%80%94_Institutional_Support_Post-Listing\" title=\"QIB at 180x \u2014 Institutional Support Post-Listing\">QIB at 180x \u2014 Institutional Support Post-Listing<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/goldline-pharmaceutical-ipo-listing-today-19-may-2026\/#About_Goldline_Pharmaceutical_The_Company_Making_Its_BSE_SME_Debut\" title=\"About Goldline Pharmaceutical: The Company Making Its BSE SME Debut\">About Goldline Pharmaceutical: The Company Making Its BSE SME Debut<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/goldline-pharmaceutical-ipo-listing-today-19-may-2026\/#Hold_or_Sell_Listing_Day_Strategy_for_Allotted_Investors\" title=\"Hold or Sell: Listing Day Strategy for Allotted Investors\">Hold or Sell: Listing Day Strategy for Allotted Investors<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/goldline-pharmaceutical-ipo-listing-today-19-may-2026\/#For_Retail_Investors_1_Lot_6000_Shares_at_Rs_43\" title=\"For Retail Investors (1 Lot = 6,000 Shares at Rs 43)\">For Retail Investors (1 Lot = 6,000 Shares at Rs 43)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/goldline-pharmaceutical-ipo-listing-today-19-may-2026\/#For_Investors_Who_Did_Not_Receive_Allotment\" title=\"For Investors Who Did Not Receive Allotment\">For Investors Who Did Not Receive Allotment<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/goldline-pharmaceutical-ipo-listing-today-19-may-2026\/#Key_Risks_at_the_Goldline_Pharmaceutical_IPO_Listing\" title=\"Key Risks at the Goldline Pharmaceutical IPO Listing\">Key Risks at the Goldline Pharmaceutical IPO Listing<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/goldline-pharmaceutical-ipo-listing-today-19-may-2026\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/goldline-pharmaceutical-ipo-listing-today-19-may-2026\/#FAQs_on_Goldline_Pharmaceutical_IPO_Listing_Today\" title=\"FAQs on Goldline Pharmaceutical IPO Listing Today\">FAQs on Goldline Pharmaceutical IPO Listing Today<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/goldline-pharmaceutical-ipo-listing-today-19-may-2026\/#What_is_the_expected_Goldline_Pharmaceutical_IPO_listing_price_today\" title=\"What is the expected Goldline Pharmaceutical IPO listing price today?\">What is the expected Goldline Pharmaceutical IPO listing price today?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/goldline-pharmaceutical-ipo-listing-today-19-may-2026\/#What_was_the_final_Goldline_Pharmaceutical_IPO_subscription\" title=\"What was the final Goldline Pharmaceutical IPO subscription?\">What was the final Goldline Pharmaceutical IPO subscription?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/goldline-pharmaceutical-ipo-listing-today-19-may-2026\/#Should_I_buy_Goldline_Pharmaceutical_on_the_listing_day_from_the_market\" title=\"Should I buy Goldline Pharmaceutical on the listing day from the market?\">Should I buy Goldline Pharmaceutical on the listing day from the market?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/goldline-pharmaceutical-ipo-listing-today-19-may-2026\/#Why_did_the_Goldline_Pharmaceutical_GMP_fall_from_Rs_25_to_Rs_15\" title=\"Why did the Goldline Pharmaceutical GMP fall from Rs 25 to Rs 15?\">Why did the Goldline Pharmaceutical GMP fall from Rs 25 to Rs 15?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Goldline_Pharmaceutical_IPO_Listing_Complete_Data\"><\/span><strong>Goldline Pharmaceutical IPO Listing: Complete Data<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><ul class=\"wp-block-list\"><li><strong>Listing Date: <\/strong>19 May 2026 (Today, 10 AM on BSE SME)<\/li>\n\n<li><strong>Issue Price (Upper Band): <\/strong>Rs 43 per share<\/li>\n\n<li><strong>Price Band: <\/strong>Rs 41 to Rs 43 per share<\/li>\n\n<li><strong>Issue Size: <\/strong>Rs 11.61 crore (27 lakh shares, 100% fresh issue)<\/li>\n\n<li><strong>Final Overall Subscription: <\/strong>840.74 times \u2014 2026&#8217;s most subscribed SME IPO<\/li>\n\n<li><strong>NII Subscription: <\/strong>1,662.04 times<\/li>\n\n<li><strong>Retail Subscription: <\/strong>881.15 times<\/li>\n\n<li><strong>QIB Subscription: <\/strong>180.22 times<\/li>\n\n<li><strong>GMP (14 May daytime peak): <\/strong>Rs 25 (58.14% premium, implied Rs 68)<\/li>\n\n<li><strong>GMP (14 May late night, pre-listing final): <\/strong>Rs 15 (34.88% premium, implied Rs 58)<\/li>\n\n<li><strong>Actual Opening Price: <\/strong>Rs 59.87 (39.2% premium over issue price of Rs 43)<\/li>\n\n<li><strong>Registrar: <\/strong>Bigshare Services Pvt Ltd<\/li>\n\n<li><strong>Market Maker: <\/strong>Nirman Share Brokers Pvt Ltd<\/li>\n\n<li><strong>Current Trading Price: <\/strong>Rs 56.77 (+Rs 13.77, +32.02% from issue price) \u2014 trading flat since 11:50 AM<\/li>\n\n<li><strong>CMD: <\/strong>Amol Laxmikant Mujumdar<\/li><\/ul><p>Track Goldline Pharmaceutical live listing price on BSE SME on the <a href=\"https:\/\/univest.in\/screeners\">Check the Univest Screener for live data<\/a>.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Actual_Listing_Opened_at_Rs_5987_Corrected_to_Rs_5677_32_%E2%80%94_How_It_Played_Out\"><\/span><strong>Actual Listing: Opened at Rs 59.87, Corrected to Rs 56.77 (+32%) \u2014 How It Played Out<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>The Goldline Pharmaceutical IPO opened at approximately Rs 59.87 on BSE SME at 9:40 AM on 19 May 2026, a 39.2 percent premium over the Rs 43 issue price. This is slightly above the GMP-implied Rs 58 (Rs 15 final GMP), validating the grey market&#8217;s pre-listing estimate. The opening was stronger than the settled GMP suggested, demonstrating genuine demand at listing from non-allotted investors trying to buy from the open market.<\/p><p>However, the sharp intraday decline from Rs 59.87 to Rs 56.66 between 9:40 AM and 11:50 AM played out exactly as predicted. The 1,662x NII oversubscription meant thousands of HNIs received tiny proportionate allotments and sold immediately at opening to recover small gains. This created a wall of selling in the first two hours. The stock has since found support and is trading flat at Rs 56.66 to Rs 56.77, up a strong 32.02 percent from the Rs 43 issue price.<\/p><p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Tap to Access Best Research Pieces on Univest<\/strong><\/a><\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"840x_Subscription_Breakdown_What_Each_Category_Means\"><\/span><strong>840x Subscription Breakdown: What Each Category Means<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"NII_at_1662x_%E2%80%94_Record_HNI_Demand_But_Small_Allotments\"><\/span><strong>NII at 1,662x \u2014 Record HNI Demand, But Small Allotments<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The NII subscription of 1,662.04 times is the critical number to understand for Goldline Pharmaceutical IPO listing day dynamics. At 1,662x oversubscription in the NII category, HNIs receive a proportionate allotment of approximately 1\/1,662 of their applied quantity. An HNI who applied the minimum 3 lots (Rs 3.87 lakh) receives approximately 5.42 shares \u2014 worth about Rs 233 at the issue price. At Rs 58 listing, this amounts to Rs 314. This means most NII allottees will immediately sell their small proportionate allocations, creating heavy selling pressure in the first 30 to 60 minutes of Goldline Pharmaceutical IPO listing trade.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Retail_at_881x_%E2%80%94_Lottery_Winners_Have_Strong_Gains\"><\/span><strong>Retail at 881x \u2014 Lottery Winners Have Strong Gains<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The retail subscription of 881.15 times means 1 in 881 retail investors who applied received allotment of exactly 1 lot (6,000 shares) via computerised lottery. At the Rs 43 issue price, this allotment cost Rs 2,58,000. At the Rs 58 expected listing price, these 6,000 shares would be worth Rs 3,48,000 \u2014 a potential gain of Rs 90,000 (34.88% return on issue price). Unlike NII allottees, retail winners received a meaningful full-lot allotment and have stronger motivation to either sell at the opening for a Rs 90,000 gain or hold for further upside.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"QIB_at_180x_%E2%80%94_Institutional_Support_Post-Listing\"><\/span><strong>QIB at 180x \u2014 Institutional Support Post-Listing<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>QIB subscription at 180.22 times is the most constructive long-term signal. Institutional investors (mutual funds, banks) assessed Goldline&#8217;s 10.48x PE at a steep discount to industry 13-15x and subscribed heavily. Post-listing, QIB allottees typically hold positions and accumulate further from the open market rather than selling at opening prices, providing medium-term price support for the Goldline Pharmaceutical IPO listing.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"About_Goldline_Pharmaceutical_The_Company_Making_Its_BSE_SME_Debut\"><\/span><strong>About Goldline Pharmaceutical: The Company Making Its BSE SME Debut<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Goldline Pharmaceutical Limited, incorporated in August 2004 in Nagpur, Maharashtra, is an asset-light pharmaceutical marketing company with zero owned manufacturing. Products are made by 15 third-party contract manufacturers per Goldline&#8217;s specifications and sold under the Goldline brand across 7 states.<\/p><ul class=\"wp-block-list\"><li><strong>5 Brand Divisions: <\/strong>Goldline Pharma (42 products \u2014 physicians, orthopaedics, ENT, surgery, neurology, gastroenterology), Cardinal (54 products \u2014 cardiology, diabetology), Aayushman (18 products \u2014 paediatrics), InLife (22 products \u2014 critical care, ICU), Wellness (10 products \u2014 cancer support)<\/li>\n\n<li><strong>FY25 Revenue: <\/strong>Rs 28.06 crore (+19% YoY) | FY24: Rs 23.57 crore | FY23: Rs 19 crore<\/li>\n\n<li><strong>FY25 PAT: <\/strong>Rs 2.83 crore (+56.4% YoY from Rs 1.81 crore)<\/li>\n\n<li><strong>ROE: <\/strong>27.34% \u2014 highest among listed pharma marketing comparables<\/li>\n\n<li><strong>PE at Issue Price: <\/strong>10.48x \u2014 vs listed peers at 13 to 15x (significant discount)<\/li>\n\n<li><strong>Geography: <\/strong>Maharashtra (44% revenue), MP, Odisha, Jharkhand, Tamil Nadu, Rajasthan, Bihar<\/li>\n\n<li><strong>IPO Proceeds: <\/strong>Debt repayment Rs 8.35 crore + general corporate purposes<\/li><\/ul><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Hold_or_Sell_Listing_Day_Strategy_for_Allotted_Investors\"><\/span><strong>Hold or Sell: Listing Day Strategy for Allotted Investors<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"For_Retail_Investors_1_Lot_6000_Shares_at_Rs_43\"><\/span><strong>For Retail Investors (1 Lot = 6,000 Shares at Rs 43)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The stock opened at Rs 59.87 and has since corrected to Rs 56.77 (+32.02%). For retail allottees who have not yet sold: the stock is currently at Rs 56.77 giving a gain of Rs 13.77 per share (Rs 82,620 on 6,000 shares). The opening Rs 59.87 gave an opportunity for Rs 1,00,620 gain. Those who sold at the open captured the maximum gain. At the current price of Rs 56.77, it still represents a 32 percent return on issue price \u2014 selling now is still a strong outcome for listing-gain investors.<\/p><p>For long-term holders who believe in Goldline&#8217;s pharma marketing growth story: keep holding with a target of Rs 70 to Rs 80 over 12 months. The 10.48x PE vs 13-15x industry average and 27.34% ROE justify a medium-term re-rating toward industry multiple.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"For_Investors_Who_Did_Not_Receive_Allotment\"><\/span><strong>For Investors Who Did Not Receive Allotment<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Investors who did not receive allotment: the predicted NII selling pressure has already occurred. The stock dropped from Rs 59.87 to Rs 56.66 and is now flat. If it dips toward Rs 54 to Rs 55 in subsequent sessions, that presents a secondary entry opportunity at a slight discount to current levels. Do not chase at Rs 56.77 if it has already run from the open \u2014 wait for a pullback.<\/p><p>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or the <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to get daily stock recommendations and insightful research pieces on Goldline Pharmaceutical live listing price, buy-sell data and BSE SME tracking!<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Key_Risks_at_the_Goldline_Pharmaceutical_IPO_Listing\"><\/span><strong>Key Risks at the Goldline Pharmaceutical IPO Listing<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><ul class=\"wp-block-list\"><li><strong>NII Selling Pressure: <\/strong>1,662x NII subscription means tens of thousands of HNIs received tiny proportionate allotments and will sell immediately, creating heavy early selling pressure.<\/li>\n\n<li><strong>GMP Retreat: <\/strong>GMP declined from Rs 25 to Rs 15 between Day 3 daytime and listing eve, suggesting grey market participants see Rs 58 not Rs 68 as realistic.<\/li>\n\n<li><strong>Weak Macro: <\/strong>Nifty is under pressure from crude above $109 and rupee at 96.17. A weak index can cap even a strong listing.<\/li>\n\n<li><strong>Related-Party Revenue: <\/strong>22% of revenue from promoter-related entities is a long-term governance risk.<\/li>\n\n<li><strong>SME Liquidity: <\/strong>Post-listing BSE SME volumes are thin. Price swings can be sharp with limited float.<\/li><\/ul><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><strong>The Goldline Pharmaceutical IPO listing<\/strong> today on 19 May 2026 is the most anticipated BSE SME debut of May 2026 after 840.74 times overall subscription, including an extraordinary 1,662x NII and 881x retail demand. The final GMP of Rs 15 (after peaking at Rs 25) implies an expected opening price of approximately Rs 58, a 34.88 percent gain over the Rs 43 issue price. The stock opened at Rs 59.87 (39.2% premium) and has corrected to Rs 56.77 (+32.02%) following NII selling pressure exactly as predicted. Retail allottees who sold at open captured Rs 1,00,620 gain per lot. Those still holding can target Rs 65 to Rs 70 medium-term. Long-term investors can hold for Rs 70 to Rs 80 over 12 months. Track the live Goldline Pharmaceutical IPO listing price from 10 AM on BSE SME on Univest. Consult a SEBI-registered advisor before any listing-day decision.<\/p><p>Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. Verify all numbers before investing. Consult a SEBI-registered advisor before making investment decisions.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FAQs_on_Goldline_Pharmaceutical_IPO_Listing_Today\"><\/span><strong>FAQs on Goldline Pharmaceutical IPO Listing Today<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_is_the_expected_Goldline_Pharmaceutical_IPO_listing_price_today\"><\/span><strong>What is the expected Goldline Pharmaceutical IPO listing price today?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p><strong>Ans. <\/strong>The Goldline Pharmaceutical IPO opened at approximately Rs 59.87 on BSE SME at 9:40 AM on 19 May 2026, a 39.2 percent premium over the Rs 43 issue price \u2014 slightly above the Rs 58 final GMP implied price. The stock dropped to Rs 56.66 on NII selling pressure and is currently trading at Rs 56.77, up 32.02 percent from the issue price. Track the live price on BSE SME via the Univest Screener.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_was_the_final_Goldline_Pharmaceutical_IPO_subscription\"><\/span><strong>What was the final Goldline Pharmaceutical IPO subscription?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p><strong>Ans. <\/strong>The Goldline Pharmaceutical IPO was subscribed 840.74 times the issue size \u2014 2026&#8217;s most oversubscribed SME IPO. NII subscribed 1,662.04 times, retail 881.15 times and QIBs 180.22 times. Total bids attracted were approximately 840.74 times the 19.68 lakh shares on offer, equivalent to approximately Rs 9,800 crore in applications for a Rs 11.61 crore issue.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Should_I_buy_Goldline_Pharmaceutical_on_the_listing_day_from_the_market\"><\/span><strong>Should I buy Goldline Pharmaceutical on the listing day from the market?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p><strong>Ans. <\/strong>Investors who missed allotment should NOT chase the opening price at Rs 58. With 1,662x NII oversubscription creating heavy selling pressure in the first 30 to 60 minutes, the stock may dip to Rs 52 to Rs 55 before finding a floor. Wait for the initial selling pressure to clear before considering buying the Goldline Pharmaceutical IPO listing from the open market.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Why_did_the_Goldline_Pharmaceutical_GMP_fall_from_Rs_25_to_Rs_15\"><\/span><strong>Why did the Goldline Pharmaceutical GMP fall from Rs 25 to Rs 15?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p><strong>Ans. <\/strong>The GMP peaked at Rs 25 during the Day 3 subscription close on 14 May as speculative grey market demand intensified. Once the subscription window closed, the GMP settled at Rs 15 (Rs 58 implied listing). At the actual listing, the stock opened at Rs 59.87 \u2014 slightly above the GMP-implied Rs 58 \u2014 confirming the grey market estimate was accurate. The post-open correction to Rs 56.77 reflects the NII selling pressure from 1,662x oversubscription, which was fully anticipated in pre-listing analysis.<\/p><p><\/p>","protected":false},"excerpt":{"rendered":"<p>The Goldline Pharmaceutical IPO listing takes place today at 10 AM on BSE SME, 19 May 2026. The Rs 11.61 crore issue attracted bids worth over Rs 9,800 crore \u2014 840.74 times the issue size \u2014 making it the most oversubscribed SME IPO of 2026 so far, per News9Live. The NII category was subscribed an<\/p>\n","protected":false},"author":35,"featured_media":91340,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1281],"tags":[3808],"class_list":["post-91321","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-ipo","tag-ipo-listing"],"metadata":{"_edit_lock":["1779171981:23"],"_last_editor_used_jetpack":["block-editor"],"rank_math_internal_links_processed":["1"],"rank_math_primary_category":["1281"],"rank_math_seo_score":["73"],"rank_math_robots":["a:2:{i:0;s:8:\"nofollow\";i:1;s:7:\"noindex\";}"],"rank_math_title":["Goldline Pharmaceutical IPO Listing Today 19 May 2026: Opens at Rs 59.87"],"rank_math_description":["Goldline Pharmaceutical IPO listing today on BSE SME 19 May 2026. Subscribed 840.74x. Opened Rs 59.87. Sharp post-open dip to Rs 56.66 on NII selling. Buy, hold or sell."],"rank_math_focus_keyword":["Goldline Pharmaceutical IPO listing"],"_thumbnail_id":["91340"],"_edit_last":["23"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["12198"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/05\/19114757\/Goldline-Pharmaceutical-IPO-1.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/91321","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/35"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=91321"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/91321\/revisions"}],"predecessor-version":[{"id":91341,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/91321\/revisions\/91341"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/91340"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=91321"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=91321"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=91321"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}